Podcasts about CRISPR

Behzad Najafian, MD, Professor, Department of Laboratory Medicine & Pathology, Department of Medicine at the University of Washington, Washington, USA discusses the use of artificial intelligence in identifying and managing lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session1-ai-in-medicine-transforming-the-landscape-of-tissue-based-diagnostics/Learning ObjectivesDescribe recent advances in the applications of AI in lysosomal disorder diagnosis and its clinical relevanceFacultyBehzad Najafian, MD Professor, Department of Laboratory Medicine & Pathology, Department of Medicine, University of WashingtonDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Behzad Najafian, MDDr. Najafian is on the Advisory Board/Consultant for Sanofi, Amicus, Avrobio, 4DMT,Sangamo, Freeline, AceLink, Relay, CRISPR, ELOXX, SPARK, UNIQURE. He receives grants/research support from Amicus. Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating stories that underscore the dynamic nature of our industry, where scientific innovation meets real-world application.Starting with a significant advancement in gene therapy, researchers have made remarkable progress in a novel approach to treating rare genetic disorders. This new methodology involves the use of CRISPR technology to edit genes directly within the human body, paving the way for potential cures once thought impossible. By targeting specific DNA sequences, scientists can now correct genetic mutations at their source. This breakthrough not only promises to transform the treatment landscape for rare diseases but also enhances our understanding of genetic disorders at a molecular level. The implications here extend beyond rare conditions, potentially offering new avenues for tackling more common genetic diseases in the future.Moving forward, let's discuss recent regulatory developments that have caught the industry's attention. The FDA has granted accelerated approval to a new oncology drug that shows promise in treating advanced forms of breast cancer. This decision was based on compelling clinical trial results demonstrating significant improvements in patient survival rates compared to existing therapies. The drug targets specific proteins involved in tumor growth, offering a more precise treatment option with potentially fewer side effects. This approval exemplifies how regulatory bodies are adapting to expedite access to life-saving treatments while ensuring rigorous safety and efficacy standards.In another noteworthy development, a Phase III clinical trial has yielded positive results for a novel Alzheimer's drug. The trial demonstrated that this drug significantly slows cognitive decline in patients with early-stage Alzheimer's disease. By targeting amyloid plaques in the brain, which are believed to contribute to neurodegeneration, this therapeutic approach represents a potential shift in how we treat this debilitating condition. These findings provide hope for millions affected by Alzheimer's and underscore the importance of continued investment in neuroscience research.Turning our attention to infectious diseases, there's exciting news from a biotech company focusing on vaccine development. They've announced encouraging preliminary data from trials of their new mRNA-based vaccine for respiratory syncytial virus (RSV). RSV is known for causing severe respiratory illness, particularly in infants and the elderly. The vaccine demonstrated robust immune responses and a favorable safety profile, suggesting it could become an important tool in preventing RSV infections globally. This development highlights the versatility of mRNA technology, which has already revolutionized COVID-19 vaccine design and holds promise for addressing various infectious diseases.In terms of industry trends, one cannot overlook the growing emphasis on personalized medicine. Recent advancements in biomarker research are enabling more tailored therapeutic approaches across multiple disease areas. By identifying specific genetic or molecular markers associated with diseases, healthcare providers can better predict patient responses to certain treatments. This shift towards precision medicine not only improves patient outcomes but also enhances healthcare efficiency by reducing trial-and-error prescribing.Lastly, we delve into an intriguing area of metabolic disorders where innovative therapeutic strategies are emerging. A biotech firm has developed a first-in-class oral medication for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and metabolic syndrome. The drug works by modulating key metabolic pathways involved in liver inflammation and fibrSupport the show

Drs Harrington and Gibson's annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington New ACS Guidelines 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes https://doi.org/10.1161/CIR.0000000000001309 ACS Guideline Chair and Vice-Chair Discussion https://www.medscape.com/viewarticle/acs-guidelines-2025-key-points-chair-and-vice-chair-2025a100093l Antiplatelet/Antithrombotic Strategies Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET) https://www.nejm.org/doi/full/10.1056/NEJMoa2507980 Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making : ENGAGE AF-TIMI 48 Trial Analysis https://doi.org/10.1016/j.jacadv.2025.102504 Factor XI Inhibitors Bristol Myers, J&J Stop Blood Clotting Drug Trial After Interim Review https://www.medscape.com/s/viewarticle/bristol-myers-j-j-stop-blood-clotting-drug-trial-after-2025a1000vqu Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention https://www.bayer.com/en/us/news-stories/oceanic-stroke OAC-Naive Subgroup From OCEANIC-AF Published https://www.medscape.com/viewarticle/novel-blood-thinner-shows-promise-atrial-fibrillation-2025a10008lz GLP-1 and Myotrophic Drugs Lilly's Next-gen Drug Shows Greater Weight Loss Than Zepbound in Late-stage Trial (TRIUMPH-4) https://www.medscape.com/s/viewarticle/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-2025a1000ys1 Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf CRISPR and Lipid Lowering Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2504747 Gene Therapy Shows Lipid Improvement but Raises Flags https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 https://www.nejm.org/doi/full/10.1056/NEJMoa2511778 Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (VESALIUS-CV) https://www.nejm.org/doi/pdf/10.1056/NEJMoa2514428 Prehospital GLP IIb/IIIa Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268 You may also like: Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech!Elise Hu, Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey got together to share the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" LINK Victor Riparbelli, “Will AI avatars eventually teach our kids?” LINKPhilip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” LINKRestoring trust in government, "Move fast...and fix democracy?" LINKTED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" LINKSarah Beery, "How AI is unearthing hidden scientific knowledge" LINKScott Loarie (of iNaturalist), "The surprising power of your nature photos" LINKDaniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" LINKJennifer Pahlka, "Coding a better government" LINKPinky Cole (Slutty Vegan), "How I make vegan food sexy" LINKJason Huang, "The high-wire act of unlocking clean energy" LINKJennifer Doudna, "CRISPR's next advance is bigger than you think" LINKJonny Sun, "You are not alone in your loneliness" LINK Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we are diving into a series of significant breakthroughs and updates that are shaping the industry landscape.Starting with a remarkable scientific advancement, researchers have made headway in the development of a new class of antibiotics that shows promise against drug-resistant bacteria. This comes as a beacon of hope in the ongoing battle against superbugs, a problem that has been escalating over the past few decades. The new antibiotics work by targeting bacterial cell walls in a novel way, which may bypass the resistance mechanisms that have rendered many traditional antibiotics ineffective. This innovation could potentially extend the lifespan of existing drugs and provide new treatment options for infections that are currently difficult to manage. It's crucial to monitor how these developments will proceed through clinical trials and regulatory scrutiny, as successful outcomes could revolutionize our approach to bacterial infections.Shifting focus to regulatory news, the FDA has recently approved a groundbreaking gene therapy for a rare genetic disorder affecting children. The therapy is designed to target and correct specific genetic mutations, offering hope for families affected by this debilitating condition. This approval not only marks a milestone for personalized medicine but also sets a precedent for future gene therapies targeting other rare diseases. The implications of such advancements are vast, as they open doors to tailored treatments that address the root causes of genetic disorders rather than just managing symptoms. As we continue to explore the potential of gene editing technologies like CRISPR, it's important to consider both the ethical and logistical challenges that accompany these scientific leaps.In clinical trial news, a late-stage study has shown promising results for a new cancer immunotherapy targeting non-small cell lung cancer. This therapy leverages the body's immune system to identify and destroy cancer cells more effectively than traditional treatments. The trial demonstrated significant improvements in patient survival rates and quality of life, underscoring the potential of immunotherapies to transform oncology care. These findings add to a growing body of evidence supporting immunotherapy as a cornerstone of future cancer treatment regimens. However, it is essential to continue researching how these therapies can be optimally combined with existing treatments to enhance outcomes and minimize side effects.Turning our attention to industry trends, there is an increasing emphasis on digital health solutions in drug development processes. Pharmaceutical companies are integrating artificial intelligence and machine learning technologies to streamline clinical trials and accelerate drug discovery. These digital tools enable more efficient data analysis, patient monitoring, and predictive modeling, which can significantly reduce development timelines and costs. As this trend gains momentum, it will be important to assess how these technologies can be best utilized without compromising data integrity or patient safety.Lastly, let's discuss an interesting development in sustainable biomanufacturing practices. Companies are investing in greener production methods that reduce environmental impact while maintaining high-quality standards for pharmaceuticals. This includes optimizing energy use, minimizing waste, and incorporating renewable resources into manufacturing processes. As regulatory bodies increasingly prioritize sustainability, we can expect these practices to become more widespread across the industry.These stories highlight how innovation continues to drive progress within pharmaceuticals and biotechnology, offering new possibilities for treatment and care. As always, it's eSupport the show

This episode is sponsored by AGNTCY. Unlock agents at scale with an open Internet of Agents.  Visit https://agntcy.org/ and add your support. Why are AI, biotechnology, and gene editing converging right now, and what does that mean for the future of humanity? In this episode of Eye on AI, host Craig Smith sits down with futurist and author Jamie Metzl to explore the superconvergence of artificial intelligence, genomics, and exponential technologies that are reshaping life on Earth. We examine the ethical and scientific realities behind human genome editing, the controversy around CRISPR babies, and why society is not yet ready to edit human embryos at scale. The conversation unpacks the complexity of biology, the risks of tech driven hubris, and why governance, values, and social norms must evolve alongside scientific breakthroughs. You will also hear a wide ranging discussion on health span versus longevity, AI and human decision making, education and inequality, and how these technologies could either unlock massive human flourishing or deepen existing global challenges depending on the choices we make today. Stay Updated: Craig Smith on X: https://x.com/craigss  Eye on A.I. on X: https://x.com/EyeOn_AI   

In this episode of 'Three Brothers No Sense', the brothers discuss Dave Chappelle's latest special and its cultural implications, the evolution of streaming services and the impact of CRISPR technology on medicine. They discuss their favorite moments of 2025 as well as how do they like the the question "what do you do for a living?" Finally, the conversation delves into the dynamics of modern relationships when the woman out earns the male.Chapters00:00 Introduction and Timely Discussions02:45 Cultural Commentary on Comedy and Media05:30 Civil Rights and Intersectionality08:12 Streaming Services and Media Consumption11:09 Technological Advances in Medicine18:07 Personal Experiences and Reflections20:26 Holiday Cheer and Closing Thoughts20:38 Christmas Preparations and Family Traditions25:22 Reflections on Loss and Family Connections32:58 Celebrating Achievements and Personal Growth46:05 Conversations About Identity and Work47:19 The Impact of Financial Management on Career Perception47:48 Social Connections and Career Paths52:45 Navigating Gender Dynamics in Earnings01:02:18 The Evolution of Gender Roles in Relationships01:07:06 Rethinking Traditional Relationship DynamicsKeywordspodcast, Chappelle, civil rights, streaming services, CRISPR, family, relationships, politics, entertainment, personal growth

In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe sit down with Glafabra CEO: Dr. Chris Hopkins, geneticist, biochemist, and biotech entrepreneur, to explore the science and strategy behind next generation cell-based gene therapies for rare diseases.With more than 25 years of experience spanning gene augmentation, rare disease biology, CRISPR licensing, and biotech formation, Dr. Hopkins shares how autologous, ex vivo engineered cell therapies may overcome key limitations of current enzyme replacement and viral gene therapies, particularly for Fabry disease.The conversation dives deep into: • How lentiviral gene augmentation in patient derived cells enables sustained enzyme production • Why redosing matters and where one time AAV therapies fall short • The scientific rationale for early intervention, including potential newborn treatment • Differences between autologous and emerging allogeneic approaches • Regulatory pathways for rare disease therapies and recent FDA developments • The role of non animal models in translational research • Montana's early access therapy law and its broader implications • Building biotech platforms amid a challenging funding environmentTopics include cell based gene therapy, Fabry disease, lentiviral vectors, stem cell engineering, rare disease drug development, regulatory science, and translational medicine. Subscribe to BioTalk Unzipped for in depth conversations with the scientists and leaders shaping the future of biomedical innovation.00:00 - Intro00:53 – Welcome to BioTalk Unzipped, Guest intro: Dr. Chris Hopkins02:10 – Guest charity: Environmental Defense Fund03:12 – His journey into rare-disease therapeutics and Glafabra05:58 – Discovering a new enzyme-deficiency therapy 06:39 – Current standard of care 07:42 – How the new autologous cell therapy works09:40 – Treating patients earlier (even newborns)10:33 – Emerging therapies - AAV gene therapy vs. cell-based therapy12:16 – Long-term results & repeat dosing14:30 – Future plans: T-cells & allogeneic approaches18:08 – New News: FDA resubmission for rare disease20:00 – Navigating FDA pathways22:06 – Non-animal testing & alternative models25:50 – Montana's early-access therapy law & medical tourism29:03 – Could other states follow?31:31 – Biotech's current funding challenges33:46 – New News: Gene therapy trial saves 4-year-old37:09 – Long-term vision for expanding therapies39:53 – Personal segment: outdoor life & skiing44:43 – Guest question on international trade Dr. Christopher Hopkinshttps://www.linkedin.com/in/christopherehopkins/ Glafabra - https://www.glafabra.com/ Environmental Defense Fund - https://www.edf.org/ Dr. Chad Briscoe

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech! Elise Hu, Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey got together to share the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" Victor Riparbelli, “Will AI avatars eventually teach our kids?” Philip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” Restoring trust in government, "Move fast...and fix democracy?" TED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" Sarah Beery, "How AI is unearthing hidden scientific knowledge" Scott Loarie (of iNaturalist), "The surprising power of your nature photos" Daniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" Jennifer Pahlka, "Coding a better government" Pinky Cole (Slutty Vegan), "How I make vegan food sexy" Jason Huang, "The high-wire act of unlocking clean energy" Jennifer Doudna, "CRISPR's next advance is bigger than you think"Jonny Sun, "You are not alone in your loneliness" Hosted on Acast. See acast.com/privacy for more information.

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech!Elise Hu of TED Talks Daily hosted a conversation with Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey, where they discussed the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" Victor Riparbelli, “Will AI avatars eventually teach our kids?” Philip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” Restoring trust in government, "Move fast...and fix democracy?" TED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" Sarah Beery, "How AI is unearthing hidden scientific knowledge" Scott Loarie (of iNaturalist), "The surprising power of your nature photos" Daniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" Jennifer Pahlka, "Coding a better government" Pinky Cole (Slutty Vegan), "How I make vegan food sexy" Jason Huang, "The high-wire act of unlocking clean energy" Jennifer Doudna, "CRISPR's next advance is bigger than you think"Jonny Sun, "You are not alone in your loneliness" Hosted on Acast. See acast.com/privacy for more information.

Nicola Longo MD, PhD, and Mark Roberts, MD Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice.The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss vectors, different strategies, modes of administration and targets in gene replacement therapies.Mark Roberts, MDNow in the broader sense, gene replacement therapy seeks to actually deliver genetic material directly into the host cell to influence gene expression. In the most simple idea, one of course has a vector, this is most commonly but not exclusively a virus, which can then be given intravenously for example, and can hope to potentially correct the condition within the individual cells using novel transgenes. Suitable candidate conditions for this as examples of genetic conditions are now well understood. And crucially, this applies not only towards some more recessive, but dominant and even accident conditions.Across the piece, one can see for example, mitochondrial problems, spinal muscular atrophy as is well known, X-linked myotubular myopathy, Duchenne muscular dystrophy, a very common condition affecting one in 3000 male individuals, Pompe disease of course, an important focus of the meeting here, but other very common conditions, for example, cystic fibrosis, immunological conditions and perhaps obviously very crucial in early work on gene therapy, hemophilia.Let's now think about the approaches to gene therapy. One can seek to work at the DNA level and gene replacement. In essence, one is trying to put a new transgene through into the nucleus that will ultimately be transcribed and translated and produce the important functional protein that is lost. Gene editing which is a very exciting new technology or CRISPR technology actually seeks to actually modify in vivo the actual mutations that are responsible for the pathogenic production of abnormal proteins and correcting these and actually producing a more normalized protein.But of course there are also RNA approaches where one seeks to actually repair the mRNA transcripts copied from the mutated gene. For example, this may be a novel approach that could be extremely useful in myotonic dystrophy, a multisystem condition. When we talk about the viral vectors, predominantly we're talking about viruses. Those such as adenoviruses and AAV viruses which have the virtue of not integrating into the host genome or at least not in a large amount, and those which deliberately seek to integrate into host genome such as retroviral or lentiviral systems that may be particularly useful for ex vivo systems.There are of course other ways to get genetic payloads into the nucleus, various polymers, nanoparticles and even cell penetrating peptides. Nanoparticles in particular is certainly on the ascendant. That being said, in a recent review of the clinical trials in gene therapy, it was certainly the viral vectors that stood out both in direct gene replacement with lentivirus and AAV, but also actually as delivery systems, for example, for gene editing. An example of what one is seeking to do with AAV, so of course one seeking to remove the native DNA, insert the new transgene directly into the vector and of course keen to make sure that there's a high transmission into the capsid producing a recombinant AAV, which then can be given as a treatment and hopefully produce a therapeutic increase in the functional protein that is deficit in the disorder.In the next part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this 8-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.Mark Roberts, MDUndoubtedly, the immune system is a major issue in these patients. It would be fantastic if we could immunotolerize our patients and indeed prevent the rejection of the therapy. We've talked about the fact that these are viral vectors and of course there may be high seroprevalence of antibodies to these viral vectors, and it's very important in the pre-screening of patients who might be eligible to understand that at the beginning. These of course can have developed over the years and of course can be part of immunological memory and therefore extremely difficult and probably impractical to actually shift.On giving the treatment though as I think we're all aware there is this problem of the innate immunity and potential therefore for acute toxicities and then a learned or adaptive response with cytotoxic T cells and antibodies which may of course become high tighter neutralizing antibodies and potentially antibodies not only against the viral vector, even the functional protein, even the transgene are all theoretical possibilities with time. The capsid, the transgene, and even the protein product can all potentially induce an immunological event. Of course, all of these would lead to both potential patient changes and then a lack of efficacy of the treatment.Indeed, there have been some serious and indeed fatal problems in the gene therapy development program as I think we're all aware. Though many of these are thankfully been overcome. Spinal muscular atrophy has a gene therapy which is licensed, but there were early patients who actually had significant problems. A patient of just 6 months of age who developed kidney failure, two other patients who actually developed liver failure.In Duchenne muscular dystrophy, a very common condition, again there were significant issues and crucially in these patients who all have cardiomyopathy, it was heart failure and cardiac arrest that were big concerns and pulmonary edema and this was seen even with a CRISPR-based technology and is perhaps is best known but has been addressed the excellent myotubular myopathy patients, four patients died and crucially quite a long time after the gene therapy emphasizing the need to monitor these patients extremely carefully and these patients died of cholestatic liver failure albeit that they had a degree of liver dysfunction.That's changed our screening of course of patients, we're now all looking in myotubular patients for liver involvement and Rett syndrome as well. Now these immunoprophylaxis treatment regimes to hopefully try and reduce the immunological reaction against the gene are certainly evolving.This is just a summary of some of the other immunosuppressive regimes used in other disorders, for example, spinal muscular atrophy, but Pompe and MPS as examples of LSDs. Certainly these regimes will continue to evolve and are going to be very important in seeking to make sure that these treatments are effective. It reminds me somewhat of what's happened with enzyme replacement therapy that the use of these immunological strategies in infants has revolutionized the utility of those treatments in early patients.In the next part, Dr. Roberts will discuss lessons learned from gene therapy trials.

Dünyanın Sonuna Yolculuk'un altıncı bölümünde Can Öz ve Ümit Alan, biyolojik risklerin ve sentetik biyolojinin yarattığı yeni tehdit alanı olan yapay salgınları ele alıyor. CRISPR teknolojisiyle genetik müdahalenin nasıl kolaylaştığı, geçmişteki biyolojik silah örnekleri, devlet dışı aktörlerin artan kapasitesi ve yapay zekânın bu alandaki rolü bölümün temel başlıklarını oluşturuyor. Kuş gribi deneyleri, laboratuvar sızıntıları, mantar kaynaklı tehditler ve biyogüvenlik tartışmaları üzerinden, modern dünyada görünmez tetikçilerin nasıl küresel krizlere dönüşebileceği yine bu bölümde değerlendiriliyor.

NB: We will be off on Dec 26 and Jan 2 and will return with new episodes on Jan 9, 2026. Today, Ali and Asif review their favourite entertainment from 2025. They discuss the best movies, TV shows, movies and books from the year (2:32). Listen to hear what they thought about ‘Fantastic 4: First Steps', ‘Happy Gilmore 2', ‘Sinners', ‘Weapons', ‘One Battle After Another', ‘A Nice Indian Boy', ‘Once Upon a Time Gaza', ‘Adolescence', ‘Mo', ‘The Pitt', ‘The Chair Company', ‘The Studio', ‘North of North, ‘The Beast in Me', etc. They also discuss some comedy specials including specials by Mike Birbiglia, Bill Burr, Steph Tolev and Roy Wood Jr. Then Asif asks Ali about the top medical news stories of the year (53:00). They discuss the good (the Nobel prize in medicine, CRISPR use in genetic disorders), the bad measles outbreaks) and the ugly (RFK Jr and MAHA). The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions.Music courtesy of Wataboi and 8er41 from PixabayContact us at doctorvcomedian@gmail.comFollow us on Social media:Twitter: @doctorvcomedianInstagram: doctorvcomedianShow Notes:Inside RFK Jr.'s first nine months leading HHS: https://www.statnews.com/2025/11/20/rfk-jr-hhs-track-record-examined-status-report/Tracking RFK Jr.'s promises to remake health in America: https://www.statnews.com/2025/09/10/rfk-jr-maha-promise-tracker-fact-check/Canada no longer measles-free as outbreaks spread: https://www.theguardian.com/world/2025/nov/11/canada-loses-measles-free-elimination-statusA huge outbreak has made Ontario the measles centre of the western hemisphere: https://www.theguardian.com/world/2025/jun/06/measles-outbreak-ontario-canadaFIFA's Gianni Infantino faces ethics complaint over Trump peace prize: https://www.aljazeera.com/news/2025/12/10/fifas-gianni-infantino-faces-ethics-complaint-over-trump-peace-prizeImmune system breakthrough wins Nobel medicine prize for US, Japan scientists: https://www.reuters.com/business/healthcare-pharmaceuticals/brunkow-ramsdell-sakaguchi-win-2025-nobel-medicine-prize-2025-10-06/?utm_source=chatgpt.comInfant with rare, incurable disease is first to successfully receive personalized gene therapy treatment: https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment Hosted on Acast. See acast.com/privacy for more information.

Mit Charlotte Grieser und Aeneas Rooch. Ihre Themen sind: - Wie Fleisch aus Quorn das Klima rettet (00:57) - Die Haustiere der Römer hatten Haustiere (11:49) - Warum klebrige Dinge ekliger sind als Schleim (21:13) - Viel Licht am Vormittag gegen Depressionen (27:11) Weitere Infos und Studien gibt's hier: Dual enhancement of mycoprotein nutrition and sustainability via CRISPR-mediated metabolic engineering of Fusarium venenatum: https://www.cell.com/trends/biotechnology/abstract/S0167-7799(25)00404-4 A centurion's monkey? Companion animals for the social elite in an Egyptian port on the fringes of the Roman Empire in the 1st and 2nd c. CE: https://www.cambridge.org/core/journals/journal-of-roman-archaeology/article/centurions-monkey-companion-animals-for-the-social-elite-in-an-egyptian-port-on-the-fringes-of-the-roman-empire-in-the-1st-and-2nd-c-ce/BC4AE30501792AF350762ADD326AE5B6 Gooey stuff: the psychophysics of unpleasantness in response to touching liquids: https://royalsocietypublishing.org/rspb/article/292/2059/20252244/356045/Gooey-stuff-the-psychophysics-of-unpleasantness-in Living in biological darkness III: Effects of low-level pre-midday lighting on markers of depression in healthy subjects: https://www.sciencedirect.com/science/article/pii/S0022395625007034?via%3Dihub SWR das Wissen: die Kraft der Dunkelheit: https://www.swr.de/swrkultur/wissen/die-kraft-der-dunkelheit-angst-ruhe-erkenntnis-das-wissen-2025-12-20-100.html Unser Podcast-Tipp der Woche: Kein Mucks! – Der Krimi-Podcast mit Bastian Pastewka https://1.ard.de/Kein_Mucks Schickt uns eure Themenvorschläge über die Spotify-Kommentarfunktion oder schreibt uns bei WhatsApp oder schickt eine Sprachnachricht: 0174/4321508 Oder per E-Mail: faktab@swr2.de Oder direkt auf http://swr.li/faktab Instagram: @charlotte.grieser @julianistin @sinologin @aeneasrooch Redaktion: Janine Funke und Chris Eckardt Idee: Christoph König

El profesor, catedrático de la UCLM, investigador y divulgador Jorge Laborda nos ha hablado de un estudio en el que esta tecnología del ADN se está usando para atender a pacientes con leucemia linfoblástica aguda

Investigadores chineses usaram o Crispr para otimizar cogumelos que sabem a carne. Agora o sabor é mais intenso e os cogumelos são mais fáceis de digerir, mais sustentáveis e também mais rápidos de produzir

In the final episode of 2025, the GEN team came together to reflect on some of the stories over the last year that they each found impactful. Some of the stories were covered in GEN's December issue, but our editors took the time to discuss some topics in a bit more depth during the podcast. The discussion began with an update on the progress of AI use in drug discovery. Cell and gene therapy was a big topic with the positive outcome for Baby KJ, while Sarepta dealt with a rollercoaster of a year with their DMD treatment, Elevidys. Research and biotech in Africa are growing and the discussion ranged from challenges to promise in research and development on the continent. This year's NIH budget cuts and impacted institutions rounded out the conversation.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, Phd, Kevin Davies, Phd, John Sterling, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: GEN Editors Reflect on Six of the Biggest Stories of the YearBy Alex Philippidis, Savannah Wiegel, Fay Lin, PhD, Kevin Davies, PhD, Uduak Thomas, and Julianna LeMieux, PhD, GEN, December 4, 2025StockWatch: Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment By Alex Philippidis, GEN Edge, August 10 StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks By Alex Philippidis, GEN Edge, August 3 FDA Probes Death of Brazilian Boy Linked to Sarepta's Elevidys GEN Edge, July 27 Second DMD Patient Dies After Treatment with Sarepta Gene Therapy By Alex Philippidis, GEN Edge, June 15 DMD Patient Dies After Treatment with Sarepta Gene Therapy By Alex Philippidis, GEN Edge, March 18From The Editor in ChiefJohn Sterling, December Issue of GEN Gene Therapy in AfricaThe State of CRISPR & Genome Editing Summit, June 11, 2025TOP 50 NIH By Alex Philippidis, GEN, December 4, 2025 FDA Cell & Gene Therapy roundtable: Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions” By Alex Philippidis, and Kevin Davies, PhD, GEN Edge, June 5, 2025Scientists in NYC Rally to Defend and Stand Up for ScienceBy Corinna Singleman, GEN, March 10, 2025Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

00:46 The gifts that sparked a love of scienceNature put a call out for readers to tell us about memorable presents that first got them interested in science, or mementos of their life in research. These include telescopes, yeast-themed wedding rings, and... cows' eyes.Nature: The gift that shaped my career in science08:12 “I am the Very Model of a Miniature Tyrannosaur”In the first of our annual festive songs celebrating the science of the past year, we tell the story of a diminutive dinosaur that turned out to be its own species.Nature Podcast: Meet the ‘Wee-rex'. Tiny tyrannosaur is its own speciesNature Video: Hotly debated dinosaur is not a tiny T. rex after all11:43 A very scientific quizAn all-star cast competes for the glory or being the winner of the Nature Podcast's 2025 festive quiz.Nature: Meet the ‘Wee-rex'. Tiny tyrannosaur is its own speciesNature: This company claimed to ‘de-extinct' dire wolves. Then the fighting startedNature Podcast: 3D-printed fake wasps help explain bad animal mimicryNature Video: ‘Aqua tweezers' manipulate particles with water wavesNature Podcast: Sapphire anvils squeeze metals atomically-thinNature Video: Vesuvius volcano turned this brain to glassNature Podcast: Ancient viral DNA helps human embryos developNature Video: Magnetic fibres give this robot a soft gripNature: These contact lenses give people infrared vision — even with their eyes shutNature Video: Is this really the world's largest mirror? Researchers put it to the testNature Podcast: World's tiniest pacemaker could revolutionize heart surgeryNature Podcast: Earth's deepest ecosystem discovered six miles below the seaNature Podcast: Nature goes inside the world's largest ‘mosquito factory' — here's the buzzNature Podcast: Apocalypse then: how cataclysms shaped human societiesNature Podcast: Honey, I ate the kids: how hunger and hormones make mice aggressive25:21 “Hard the Hydrogel is Stuck”Our second festive song is an ode to a rubber duck that was stuck to a rock, thanks to a newly designed, super-adhesive hydrogel.Nature Podcast: Underwater glue shows its sticking power in rubber duck testNature Video: Why did researchers stick a duck to a rock? To show off their super glue28:42 Nature's 10Each year, Nature's 10 highlights some of the people who have helped shape science over the past 12 months. We hear about a few of the people who made the 2025 list, including: a civil servant who stood up for evidence-based public-health policy; the science sleuth who revealed a retraction crisis at Indian universities; and the baby whose life was saved by the first personalized CRISPR therapy.Nature: Nature's 10Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

In this episode of The Brainstorm, we delve into the groundbreaking advancements in gene editing, focusing on its potential to transform healthcare. We explore the shift from treating rare diseases to tackling common killers like cardiovascular disease, and discover how CRISPR technology is paving the way for a new era in medical treatment.If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn't mean we don't have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we're sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Wolf.financial, and sponsored by Public. Tune in every week as we react to the latest in innovation. Here and there we'll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK's quick takes on what's going on in tech today.Key Points From This Episode:CRISPR-based gene editing is moving from treating rare diseases to addressing common conditions like cardiovascular disease.The transition from ex vivo to in vivo gene editing could simplify treatment processes significantly.Lipid nanoparticle delivery is a key advancement enabling in vivo gene editing.The potential market for in vivo gene editing treatments is vast, with significant implications for healthcare costs and patient outcomes.To learn more about WOLF: https://wolf.financialTo learn more about Public: https://public.com/Relevant Links:https://www.ark-invest.com/newsletters/issue-491

Happy holidays listeners! With the year coming to an end, Cathy Gildenhorn, Beth Glassman, and our Executive Producer Kira Dineen have been reflecting back on a full three years of “It Happened To Me”. We've produced nearly 75 episodes and learned so much along the way. A good chunk of them have been exploring rare diseases and hearing people's journeys from early symptoms, to diagnosis, to treatment, and beyond. With this in mind, we want to revisit an episode that takes a more macro view on rare diseases.  If you're a long time listener of the show, you may know Kira Dineen is not only produces the show, but is also a practicing genetic counselor, so we thought it would be interesting to bring her in front of the mic in this episode to talk about how genetic counselors can help those in the rare disease community.    Genetic Counselor, and our podcast co-producer, Kira Dineen shares her insight on when to pursue genetic counseling and how genetic counselors can help people in the rare disease community. Co-producer Kira Dineen, MS, LCGC, CG(ASCP)CM has over a decade of podcast experience fueled by a passion for science communication. She has hosted and produced 7 podcasts. Her multi-award winning podcast, "DNA Today", is in the top 1% of podcasts globally. She was accepted into The Podcast Academy and has served as a Blue Ribbon Panelist for The Ambies. Kira received her Diagnostic Genetic Bachelor's of Science degree at the University of Connecticut and is a certified Cytogenetic Technologist. She received her Master's of Science in Human Genetics at Sarah Lawrence College in New York and is a licensed certified genetic counselor currently practicing in Connecticut.  On This Episode We Answer: When should a person or couple consider genetic counseling? Is a referral required to see a genetic counselor? Does insurance cover genetic counseling for this? Is genetic testing done before the visit?  How many visits are we talking about? Do you ever suggest adoption as an option? When? How do you help people with genetic conditions? Why get tested at all? What have you learned from interviews with patients and rare disease advocates? Do you recommend joining rare disease advocacy groups? Why study rare diseases? What is CRISPR? How could this help treat…or even cure…genetic conditions?  You produce a rare disease podcast that focuses on nano rare diseases. What's a nano-rare disease? Stay tuned for the next new episode of It Happened To Me! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.  It Happened To Me is created and hosted by Cathy Gildenhorn and Beth Glassman. Steve Holsonback is our media engineer and co-producer. DNA Today's Kira Dineen is our marketing lead and co-producer. Ashlyn Enokian is our graphic designer.  See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

This is a recap of the top 10 posts on Hacker News on December 12, 2025. This podcast was generated by wondercraft.ai (00:30): Nokia N900 NecromancyOriginal post: https://news.ycombinator.com/item?id=46239177&utm_source=wondercraft_ai(01:51): Google de-indexed Bear Blog and I don't know whyOriginal post: https://news.ycombinator.com/item?id=46239752&utm_source=wondercraft_ai(03:12): Epic celebrates "the end of the Apple Tax" after court win in iOS payments caseOriginal post: https://news.ycombinator.com/item?id=46245398&utm_source=wondercraft_ai(04:34): SQLite JSON at full index speed using generated columnsOriginal post: https://news.ycombinator.com/item?id=46243904&utm_source=wondercraft_ai(05:55): macOS 26.2 enables fast AI clusters with RDMA over ThunderboltOriginal post: https://news.ycombinator.com/item?id=46248644&utm_source=wondercraft_ai(07:16): The Tor Project is switching to RustOriginal post: https://news.ycombinator.com/item?id=46243543&utm_source=wondercraft_ai(08:38): CRISPR fungus: Protein-packed, sustainable, and tastes like meatOriginal post: https://news.ycombinator.com/item?id=46239629&utm_source=wondercraft_ai(09:59): Koralm RailwayOriginal post: https://news.ycombinator.com/item?id=46242871&utm_source=wondercraft_ai(11:20): Id Software devs form "wall-to-wall" unionOriginal post: https://news.ycombinator.com/item?id=46246845&utm_source=wondercraft_ai(12:42): The tiniest yet real telescope I've builtOriginal post: https://news.ycombinator.com/item?id=46241763&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai

Welcome back to the Information Entropy Podcast where this week we return to finish off our investigation into CRISPR and genetic engineering! In this episode, we skip straight to the fun stuff where Mitch explores the potential for humans and AI to hack the biological instructions with malicious intentions... how far away are we from AI altering our DNA? Tom takes a look at Gene Drives, a system that allows humans to alter the inheritance chance of positive and negative genes and traits that could have devastating ecological consequences if unleashed on the world. In addition to that, the boys get ahead of themselves and rant about Christmas movies and the capitalistic nature of the holiday season. Music: HOME – AWAY

In this episode of Nephilim Death Squad, we sit down with Bennett from Broadcasting Seeds to explore one of the wildest and most important concepts we've ever covered: Dark DNA, generational trauma, Nephilim genetics, ancient bloodline corruption, and how modern science is accidentally proving the Bible right.We break down:• Dark DNA & “junk DNA” — what science is finally discovering• Generational trauma vs generational iniquity• Epigenetics, curses, blessings & biblical bloodline warfare• Why certain families carry spiritual “open doors”• CRISPR, mRNA tech, hybrid beings & the return of the Nephilim• How trauma creates spiritual gateways• Why some bloodlines attract the supernatural• How demonic strongholds operate inside the human soul• Rituals, roots, pharmakeia & ancient genetic manipulation• Dogmen, giants, hybrids, and military experimentation• What repentance actually does to the spirit–and the DNAThis episode dives straight into biblical science, spiritual warfare, ancient technology, Nephilim theory, and why humans carry more than just memories in their blood.If you've ever wondered why certain sins, struggles, gifts, or supernatural events follow specific families… this one will hit hard.

In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease.Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech founder, and now leader inside a global pharmaceutical company. The conversation explores how human genetics, CRISPR base editing, lipid nanoparticle delivery, and asymmetric learning converged to create a potential lifelong solution to cardiovascular disease.They also dive deep into the ethics of gene editing, global access and pricing, early intervention versus chronic care, FDA regulatory challenges, and what the Verve–Lilly acquisition means for the future of cardiometabolic medicine.This episode is a must-listen for anyone interested in biotech innovation, gene therapy, cardiovascular disease, and the future of preventive medicine. 00:00 Introduction and Guest Welcome01:16 Sekar Kathiresan's Early Life and Education03:19 Founding Verve and Transition to Entrepreneurship05:35 The Science Behind Verve's Mission10:27 Challenges and Breakthroughs in Gene Editing20:05 Regulatory Hurdles and First Human Trials25:11 Ethical Considerations in Gene Editing27:06 Introduction to Drug Delivery and Ethical Considerations27:51 Historical Context and Pioneers in Medical Procedures28:35 Commercial and Ethical Challenges in Medicine29:32 Innovations in Cardiovascular Treatments32:49 The Role of Gene Editing in Long-term Health37:55 Strategic Partnerships and Industry Insights45:08 Reflections on the US Medical Ecosystem48:54 Conclusion and Future Outlook Keep up with Sekar Kathiresan;LinkedIn: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/Website: https://www.lilly.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/ 

In his recent book, Randy Kay writes, “For centuries, Revelation 13 sounded impossible. Today, it reads more like a headline.” Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at https://youtube.com/calvaryhanford — Prophecy Update #833 – Are You […]

What happens when the law meets the natural world? In this episode of LawPod, Dr Jocelyn Bosse joins Dr Ciarán O'Kelly to explore the fascinating intersection of intellectual property rights, biodiversity, and food security. Fresh from being awarded the prestigious UKRI Future Leaders Fellowship, Dr Bosse shares insights from her ambitious research project, ‘A Century of Propertising Plants: examining the role of intellectual property law in protecting biodiversity and food security', which examines how plant IP laws have influenced agriculture over the past hundred years—and what that means for the future. From the origins of plant patents in the 1930s to today's debates on CRISPR gene editing, this conversation unpacks the tensions between innovation and biodiversity, the role of law in shaping science, and the global implications for food security. Whether you're curious about how IP law affects what ends up on your plate or the ethical questions behind controlling nature, this episode offers a deep dive into one of the most overlooked areas of law. A PhD studentship funded by the Department for the Economy (DfE) is also available with Dr Bosse. https://law.qub.ac.uk/schools/SchoolofLaw/news/qub-dfe-plants-biodiversity-food-security.html

As the popularity of online prediction markets grows, correspondent Anderson Cooper sits down with Polymarket founder and CEO Shayne Coplan in his first network television interview. The 27-year-old newly minted billionaire talks about his platform, where users can bet on politics and pop culture, sports and finance, even war and peace, and how all that data can be used to forecast the future. After a three-year U.S. ban, Coplan explains how Polymarket works, and how the company finds itself poised to reenter the U.S. market with backing from Washington, Wall Street and Silicon Valley.  America's next wave of scientific talent may come from Lambert High School, where students used CRISPR to develop a promising new way to detect and treat Lyme disease, which affects nearly half a million Americans each year. Correspondent Bill Whitaker meets these “CRISPR kids” as they take their breakthrough to iGEM—the global biotech Olympics in Paris—and face off against the world's new rising force in biotechnology: China.  Barcelona's 18-year-old soccer phenom Lamine Yamal has captivated fans with his improvisation and flair. Already, he is considered a generational talent and an heir to the great Lionel Messi. Correspondent Jon Wertheim meets Lamine Yamal in his home country of Spain to talk about his rapid ascent ahead of next summer's World Cup in North America. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

CRISPR-based gene editing has revolutionized modern biology, but these tools are unable to access the DNA that resides inside mitochondria. Researchers are eager to access and edit this DNA to understand more about the energy production and the mutations that can cause incurable mitochondrial diseases.Because CRISPR can't help with these problems, researchers have been looking for other ways to precisely edit the mitochrondrial genome. And the past few years have brought some success — if researchers can make editing safe and accurate enough, it could eventually be used to treat, and even cure, these genetic conditions.This is an audio version of our Feature: Faulty mitochondria cause deadly diseases — fixing them is about to get a lot easier Hosted on Acast. See acast.com/privacy for more information.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering from this debilitating condition. The latest Phase 3 trial results have shown a promising reduction in cognitive decline among participants, offering a glimmer of hope for millions affected by Alzheimer's worldwide. The study, conducted over 18 months, involved more than 1,500 patients and demonstrated a statistically significant slowing of disease progression compared to placebo. This could mark a pivotal moment in Alzheimer's treatment, shifting the paradigm from symptomatic relief to disease modification.In regulatory news, the FDA has granted approval to a new gene therapy for hemophilia B. This therapy, developed using cutting-edge CRISPR technology, offers a potential cure for patients who have long relied on regular infusions to manage their bleeding disorder. By directly editing the genes responsible for clotting factor production, this therapy can potentially provide long-term relief with just a single administration. The approval follows extensive clinical trials that showed sustained increases in clotting factor levels and a dramatic reduction in bleeding episodes among participants. This development not only underscores the growing impact of genomic medicine but also highlights the regulatory body's commitment to advancing innovative treatments that meet unmet medical needs.Shifting focus, there's an intriguing trend emerging in oncology drug development. The industry is increasingly adopting personalized medicine approaches, tailoring treatments based on individual genetic profiles. This shift is particularly evident in the rise of targeted therapies and combination regimens designed to tackle cancer at its genetic roots. A recent study demonstrated how combining targeted therapies with immune checkpoint inhibitors can enhance treatment efficacy in certain types of cancer, such as melanoma and non-small cell lung cancer. By understanding the specific mutations driving tumor growth and leveraging the body's immune response, these combinations are setting new standards for cancer care.In another significant development, researchers have unveiled promising results from an innovative mRNA vaccine trial aimed at combating infectious diseases beyond COVID-19. The technology, which gained prominence during the pandemic, is now being applied to other viral threats like influenza and RSV. Early-phase clinical trials have shown robust immune responses and favorable safety profiles, suggesting mRNA vaccines could soon revolutionize how we approach vaccination for a variety of pathogens. This versatility and rapid development timeline make mRNA platforms particularly attractive for addressing emerging infectious diseases swiftly.Meanwhile, a new study has raised awareness about antibiotic resistance—a growing concern globally. Scientists have developed an advanced diagnostic tool capable of rapidly identifying bacterial infections and their resistance profiles within hours instead of days. This innovation can significantly impact how clinicians prescribe antibiotics, ensuring targeted treatments that minimize resistance development. By providing real-time insights into bacterial genetics and resistance mechanisms, this tool empowers healthcare providers to make informed decisions that preserve antibiotic efficacy for future generations.Lastly, let's toSupport the show

Welcome back to the Information Entropy Podcast! In this episode, we break down the building blocks of life, from atoms and molecules to DNA and RNA. We then dive into the world of genetic engineering, exploring what CRISPR is, how it works, and why it's become one of the most important tools in modern biology and why scientists are so eager to rewrite genetic code. This week is Part 1 where we set the stage and foundational knowledge, next week we will explore the possible exploitations of such a technology… good and bad! Music: HOME – AWAY

This week, we look at new studies on early aspirin discontinuation after myocardial infarction, an antiviral pill for dengue prevention, and CRISPR-based gene editing for lipid disorders. We review bedside clinical teaching and present a complex case of seizures and visual disturbances. Perspectives explore antidepressant safety in pregnancy, restoring trust in public health, academic medical centers' venture investments, and a young physician's wrinkled white coat.

After our “AILIEN The Final Card” show, it became apparent that the push to grant mass “amnesty” to every person and agency involved in black budget programs was a dangerous narrative gaining more traction by the day, and now compounded by an executive order from the White House titled “Launching the Genesis Mission.” This program seeks to support, along with the AI regulation moratorium of the BBB, the narrative that “America is in a race for global technology dominance in the development of artificial intelligence (AI).” The first section states: “the challenges we face require a historic national effort, comparable in urgency and ambition to the Manhattan Project that was instrumental to our victory in World War II.” But what suddenly changed? Have other countries cracked the AI egg entirely or has, as the UFO community suggests, they reverse engineered alien tech fully? Even so, a dangerous nationwide Manhattan Project should be a secret, not a public initiative. One part of the EO says the goal is to develop "AI-enabled predictive models, simulation models, and design optimization tools,” things that have been sold to the public over and over again, from climate change to pandemic models, but which have all been wrong. But if AI says something is true based on a model, it must be correct. However, if AI is merely saying what is most likely based on current actions, like a tarot reading, then if all current policies are designed for war then isn't that what we will get? Isn't that what Alex Karp of Palantir said would happen? And isn't “Genesis” also “skynet”?For those left waiting for something “big” to happen it will be disappointing to learn that it already has. Engineered smart/micro-dust is currently turning the world into a giant sensor, while Sam Altman of the Stargate Project, OpenAI, and the Orb, is now funding CRISPR-based embryo gene editing as the alterer-of-man.And to keep us entertained during this slow-burn apocalyptic invasion, we have KION, an AI-created K-pop star who's clearly created with all he best black goo moments from Taylor Swift, Lady Gaga, Billie Eilish, and the like. It all makes sense if the gift of “UFO technology” may in fact be a series of blueprints to build the alien mind on earth; the name KION, from various languages, translates to ancient-foundation-leader-possessed. In other words, Lovecraft's Old Ones once more. But IT is being sold as a sexy black goo princess.  *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.WEBSITEFREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVE-X / TWITTERFACEBOOKINSTAGRAMYOUTUBERUMBLE - BUY ME A COFFEECashApp: $rdgable PAYPAL: rdgable1991@gmail.comRyan's Books: https://thesecretteachings.info-EMAIL: rdgable@yahoo.com / rdgable1991@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the latest example raising concerns that the agency is shifting the regulatory goalposts amid a lack of transparency. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin explains how the absence of advisory committee meetings at FDA is in part to blame for a lack of consistency in decision-making and divergence from decisions taken by other global regulatory agencies. VP and Editor-in-Chief Simone Fishburn then discusses the takeaways from Franck Le Deu's guest commentary on how China's biotech ecosystem is evolving, and whether government support for the sector is helping or hindering its overall health. BioCentury's analysts also discuss whether conventional CRISPR therapies will ever be commercially successful, and what's next for NLRP3 inhibitors to treat obesity following the first set of Phase II data for the class.We'd also like to invite our listeners to participate in our important survey about their experiences interacting with FDA. To take the survey, please go to BioCentury's FDA Sentiment Survey. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657698#FDARegulation #CRISPRTherapies #NLRP3Inhibitors #ChinaBiotech #DrugApproval00:01 - Sponsor Message: Voyager Therapeutics01:31 - FDA Sydnexis CRL07:36 - CDC Vaccine Claims09:55 - China's Innovation Arc16:49 - CRISPR Commercial Viability 26:39 - NLRP3 for ObesityTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Synopsis: This episode is proudly sponsored by Quartzy. Biotech is undergoing a scientific redesign, and Jason Kelly reveals to host Alok Tayi how automation, AI-ready datasets, and modular lab technologies are reshaping the future of R&D. Jason explains why legacy biopharma data—messy, inconsistent, and lacking metadata—cannot power modern machine learning, and why the industry must generate entirely new, massively standardized experimental datasets to unlock AI's true potential. He walks through Ginkgo's evolution from platform partnerships to a next-generation CRO built for AI-driven discovery, offering industrialized functional genomics, mammalian engineering, CRISPR libraries, and high-throughput developability assays at unprecedented scale. Jason also describes how Ginkgo's reconfigurable automation systems—robotic building blocks that replace 18-month custom builds—are democratizing high-throughput experimentation and making advanced lab infrastructure as flexible as cloud computing. Together, Jason and Alok explore how the fusion of automation and AI can collapse R&D timelines, rewrite cost structures, and enable thousands of new biotech companies to test ideas faster than ever before. For scientists, engineers, and AI practitioners, this episode offers a compelling look at the new scientific architecture emerging at the intersection of robotics, data, and programmable biology. Biography: Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. He took the company public and raised $1.6B in the largest US biotech public listing to date in 2021. Today the company is pioneering autonomous labs that accelerate bioengineering across biopharma, agriculture, and industrial biotech industries. Jason also previously served as the Chair of the US National Security Commission on Emerging Biotechnology which oversees how advancements in emerging biotechnology will shape current and future activities of the US Department of Defense. Prior to Ginkgo, Jason received B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering all from MIT.

How can you write science-based fiction without info-dumping your research? How can you use AI tools in a creative way, while still focusing on a human-first approach? Why is adapting to the fast pace of change so difficult and how can we make the most of this time? Jamie Metzl talks about Superconvergence and more. In the intro, How to avoid author scams [Written Word Media]; Spotify vs Audible audiobook strategy [The New Publishing Standard]; Thoughts on Author Nation and why constraints are important in your author life [Self-Publishing with ALLi]; Alchemical History And Beautiful Architecture: Prague with Lisa M Lilly on my Books and Travel Podcast. Today's show is sponsored by Draft2Digital, self-publishing with support, where you can get free formatting, free distribution to multiple stores, and a host of other benefits. Just go to www.draft2digital.com to get started. This show is also supported by my Patrons. Join my Community at Patreon.com/thecreativepenn Jamie Metzl is a technology futurist, professional speaker, entrepreneur, and the author of sci-fi thrillers and futurist nonfiction books, including the revised and updated edition of Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World. You can listen above or on your favorite podcast app or read the notes and links below. Here are the highlights and the full transcript is below. Show Notes How personal history shaped Jamie's fiction writing Writing science-based fiction without info-dumping The super convergence of three revolutions (genetics, biotech, AI) and why we need to understand them holistically Using fiction to explore the human side of genetic engineering, life extension, and robotics Collaborating with GPT-5 as a named co-author How to be a first-rate human rather than a second-rate machine You can find Jamie at JamieMetzl.com. Transcript of interview with Jamie Metzl Jo: Jamie Metzl is a technology futurist, professional speaker, entrepreneur, and the author of sci-fi thrillers and futurist nonfiction books, including the revised and updated edition of Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World. So welcome, Jamie. Jamie: Thank you so much, Jo. Very happy to be here with you. Jo: There is so much we could talk about, but let's start with you telling us a bit more about you and how you got into writing. From History PhD to First Novel Jamie: Well, I think like a lot of writers, I didn't know I was a writer. I was just a kid who loved writing. Actually, just last week I was going through a bunch of boxes from my parents' house and I found my autobiography, which I wrote when I was nine years old. So I've been writing my whole life and loving it. It was always something that was very important to me. When I finished my DPhil, my PhD at Oxford, and my dissertation came out, it just got scooped up by Macmillan in like two minutes. And I thought, “God, that was easy.” That got me started thinking about writing books. I wanted to write a novel based on the same historical period – my PhD was in Southeast Asian history – and I wanted to write a historical novel set in the same period as my dissertation, because I felt like the dissertation had missed the human element of the story I was telling, which was related to the Cambodian genocide and its aftermath. So I wrote what became my first novel, and I thought, “Wow, now I'm a writer.” I thought, “All right, I've already published one book. I'm gonna get this other book out into the world.” And then I ran into the brick wall of: it's really hard to be a writer. It's almost easier to write something than to get it published. I had to learn a ton, and it took nine years from when I started writing that first novel, The Depths of the Sea, to when it finally came out. But it was such a positive experience, especially to have something so personal to me as that story. I'd lived in Cambodia for two years, I'd worked on the Thai-Cambodian border, and I'm the child of a Holocaust survivor. So there was a whole lot that was very emotional for me. That set a pattern for the rest of my life as a writer, at least where, in my nonfiction books, I'm thinking about whatever the issues are that are most important to me. Whether it was that historical book, which was my first book, or Hacking Darwin on the future of human genetic engineering, which was my last book, or Superconvergence, which, as you mentioned in the intro, is my current book. But in every one of those stories, the human element is so deep and so profound. You can get at some of that in nonfiction, but I've also loved exploring those issues in deeper ways in my fiction. So in my more recent novels, Genesis Code and Eternal Sonata, I've looked at the human side of the story of genetic engineering and human life extension. And now my agent has just submitted my new novel, Virtuoso, about the intersection of AI, robotics, and classical music. With all of this, who knows what's the real difference between fiction and nonfiction? We're all humans trying to figure things out on many different levels. Shifting from History to Future Tech Jo: I knew that you were a polymath, someone who's interested in so many things, but the music angle with robotics and AI is fascinating. I do just want to ask you, because I was also at Oxford – what college were you at? Jamie: I was in St. Antony's. Jo: I was at Mansfield, so we were in that slightly smaller, less famous college group, if people don't know. Jamie: You know, but we're small but proud. Jo: Exactly. That's fantastic. You mentioned that you were on the historical side of things at the beginning and now you've moved into technology and also science, because this book Superconvergence has a lot of science. So how did you go from history and the past into science and the future? Biology and Seeing the Future Coming Jamie: It's a great question. I'll start at the end and then back up. A few years ago I was speaking at Lawrence Livermore National Laboratory, which is one of the big scientific labs here in the United States. I was a guest of the director and I was speaking to their 300 top scientists. I said to them, “I'm here to speak with you about the future of biology at the invitation of your director, and I'm really excited. But if you hear something wrong, please raise your hand and let me know, because I'm entirely self-taught. The last biology course I took was in 11th grade of high school in Kansas City.” Of course I wouldn't say that if I didn't have a lot of confidence in my process. But in many ways I'm self-taught in the sciences. As you know, Jo, and as all of your listeners know, the foundation of everything is curiosity and then a disciplined process for learning. Even our greatest super-specialists in the world now – whatever their background – the world is changing so fast that if anyone says, “Oh, I have a PhD in physics/chemistry/biology from 30 years ago,” the exact topic they learned 30 years ago is less significant than their process for continuous learning. More specifically, in the 1990s I was working on the National Security Council for President Clinton, which is the president's foreign policy staff. My then boss and now close friend, Richard Clarke – who became famous as the guy who had tragically predicted 9/11 – used to say that the key to efficacy in Washington and in life is to try to solve problems that other people can't see. For me, almost 30 years ago, I felt to my bones that this intersection of what we now call AI and the nascent genetics revolution and the nascent biotechnology revolution was going to have profound implications for humanity. So I just started obsessively educating myself. When I was ready, I started writing obscure national security articles. Those got a decent amount of attention, so I was invited to testify before the United States Congress. I was speaking out a lot, saying, “Hey, this is a really important story. A lot of people are missing it. Here are the things we should be thinking about for the future.” I wasn't getting the kind of traction that I wanted. I mentioned before that my first book had been this dry Oxford PhD dissertation, and that had led to my first novel. So I thought, why don't I try the same approach again – writing novels to tell this story about the genetics, biotech, and what later became known popularly as the AI revolution? That led to my two near-term sci-fi novels, Genesis Code and Eternal Sonata. On my book tours for those novels, when I explained the underlying science to people in my way, as someone who taught myself, I could see in their eyes that they were recognizing not just that something big was happening, but that they could understand it and feel like they were part of that story. That's what led me to write Hacking Darwin, as I mentioned. That book really unlocked a lot of things. I had essentially predicted the CRISPR babies that were born in China before it happened – down to the specific gene I thought would be targeted, which in fact was the case. After that book was published, Dr. Tedros, the Director-General of the World Health Organization, invited me to join the WHO Expert Advisory Committee on Human Genome Editing, which I did. It was a really great experience and got me thinking a lot about the upside of this revolution and the downside. The Birth of Superconvergence Jamie: I get a lot of wonderful invitations to speak, and I have two basic rules for speaking: Never use notes. Never ever. Never stand behind a podium. Never ever. Because of that, when I speak, my talks tend to migrate. I'd be speaking with people about the genetics revolution as it applied to humans, and I'd say, “Well, this is just a little piece of a much bigger story.” The bigger story is that after nearly four billion years of life on Earth, our one species has the increasing ability to engineer novel intelligence and re-engineer life. The big question for us, and frankly for the world, is whether we're going to be able to use that almost godlike superpower wisely. As that idea got bigger and bigger, it became this inevitable force. You write so many books, Jo, that I think it's second nature for you. Every time I finish a book, I think, “Wow, that was really hard. I'm never doing that again.” And then the books creep up on you. They call to you. At some point you say, “All right, now I'm going to do it.” So that was my current book, Superconvergence. Like everything, every journey you take a step, and that step inspires another step and another. That's why writing and living creatively is such a wonderfully exciting thing – there's always more to learn and always great opportunities to push ourselves in new ways. Balancing Deep Research with Good Storytelling Jo: Yeah, absolutely. I love that you've followed your curiosity and then done this disciplined process for learning. I completely understand that. But one of the big issues with people like us who love the research – and having read your Superconvergence, I know how deeply you go into this and how deeply you care that it's correct – is that with fiction, one of the big problems with too much research is the danger of brain-dumping. Readers go to fiction for escapism. They want the interesting side of it, but they want a story first. What are your tips for authors who might feel like, “Where's the line between putting in my research so that it's interesting for readers, but not going too far and turning it into a textbook?” How do you find that balance? Jamie: It's such a great question. I live in New York now, but I used to live in Washington when I was working for the U.S. government, and there were a number of people I served with who later wrote novels. Some of those novels felt like policy memos with a few sex scenes – and that's not what to do. To write something that's informed by science or really by anything, everything needs to be subservient to the story and the characters. The question is: what is the essential piece of information that can convey something that's both important to your story and your character development, and is also an accurate representation of the world as you want it to be? I certainly write novels that are set in the future – although some of them were a future that's now already happened because I wrote them a long time ago. You can make stuff up, but as an author you have to decide what your connection to existing science and existing technology and the existing world is going to be. I come at it from two angles. One: I read a huge number of scientific papers and think, “What does this mean for now, and if you extrapolate into the future, where might that go?” Two: I think about how to condense things. We've all read books where you're humming along because people read fiction for story and emotional connection, and then you hit a bit like: “I sat down in front of the president, and the president said, ‘Tell me what I need to know about the nuclear threat.'” And then it's like: insert memo. That's a deal-killer. It's like all things – how do you have a meaningful relationship with another person? It's not by just telling them your story. Even when you're telling them something about you, you need to be imagining yourself sitting in their shoes, hearing you. These are very different disciplines, fiction and nonfiction. But for the speculative nonfiction I write – “here's where things are now, and here's where the world is heading” – there's a lot of imagination that goes into that too. It feels in many ways like we're living in a sci-fi world because the rate of technological change has been accelerating continuously, certainly for the last 12,000 years since the dawn of agriculture. It's a balance. For me, I feel like I'm a better fiction writer because I write nonfiction, and I'm a better nonfiction writer because I write fiction. When I'm writing nonfiction, I don't want it to be boring either – I want people to feel like there's a story and characters and that they can feel themselves inside that story. Jo: Yeah, definitely. I think having some distance helps as well. If you're really deep into your topics, as you are, you have to leave that manuscript a little bit so you can go back with the eyes of the reader as opposed to your eyes as the expert. Then you can get their experience, which is great. Looking Beyond Author-Focused AI Fears Jo: I want to come to your technical knowledge, because AI is a big thing in the author and creative community, like everywhere else. One of the issues is that creators are focusing on just this tiny part of the impact of AI, and there's a much bigger picture. For example, in 2024, Demis Hassabis from Google DeepMind and his collaborative partner John Jumper won the Nobel Prize for Chemistry with AlphaFold. It feels to me like there's this massive world of what's happening with AI in health, climate, and other areas, and yet we are so focused on a lot of the negative stuff. Maybe you could give us a couple of things about what there is to be excited and optimistic about in terms of AI-powered science? Jamie: Sure. I'm so excited about all of the new opportunities that AI creates. But I also think there's a reason why evolution has preserved this very human feeling of anxiety: because there are real dangers. Anybody who's Pollyanna-ish and says, “Oh, the AI story is inevitably positive,” I'd be distrustful. And anyone who says, “We're absolutely doomed, this is the end of humanity,” I'd also be distrustful. So let me tell you the positives and the negatives, and maybe some thoughts about how we navigate toward the former and away from the latter. AI as the New Electricity Jamie: When people think of AI right now, they're thinking very narrowly about these AI tools and ChatGPT. But we don't think of electricity that way. Nobody says, “I know electricity – electricity is what happens at the power station.” We've internalised the idea that electricity is woven into not just our communication systems or our houses, but into our clothes, our glasses – it's woven into everything and has super-empowered almost everything in our modern lives. That's what AI is. In Superconvergence, the majority of the book is about positive opportunities: In healthcare, moving from generalised healthcare based on population averages to personalised or precision healthcare based on a molecular understanding of each person's individual biology. As we build these massive datasets like the UK Biobank, we can take a next jump toward predictive and preventive healthcare, where we're able to address health issues far earlier in the process, when interventions can be far more benign. I'm really excited about that, not to mention the incredible new kinds of treatments – gene therapies, or pharmaceuticals based on genetics and systems-biology analyses of patients. Then there's agriculture. Over the last hundred years, because of the technologies of the Green Revolution and synthetic fertilisers, we've had an incredible increase in agricultural productivity. That's what's allowed us to quadruple the global population. But if we just continue agriculture as it is, as we get towards ten billion wealthier, more empowered people wanting to eat like we eat, we're going to have to wipe out all the wild spaces on Earth to feed them. These technologies help provide different paths toward increasing agricultural productivity with fewer inputs of land, water, fertiliser, insecticides, and pesticides. That's really positive. I could go on and on about these positives – and I do – but there are very real negatives. I was a member of the WHO Expert Advisory Committee on Human Genome Editing after the first CRISPR babies were very unethically created in China. I'm extremely aware that these same capabilities have potentially incredible upsides and very real downsides. That's the same as every technology in the past, but this is happening so quickly that it's triggering a lot of anxieties. Governance, Responsibility, and Why Everyone Has a Role Jamie: The question now is: how do we optimise the benefits and minimise the harms? The short, unsexy word for that is governance. Governance is not just what governments do; it's what all of us do. That's why I try to write books, both fiction and nonfiction, to bring people into this story. If people “other” this story – if they say, “There's a technology revolution, it has nothing to do with me, I'm going to keep my head down” – I think that's dangerous. The way we're going to handle this as responsibly as possible is if everybody says, “I have some role. Maybe it's small, maybe it's big. The first step is I need to educate myself. Then I need to have conversations with people around me. I need to express my desires, wishes, and thoughts – with political leaders, organisations I'm part of, businesses.” That has to happen at every level. You're in the UK – you know the anti-slavery movement started with a handful of people in Cambridge and grew into a global movement. I really believe in the power of ideas, but ideas don't spread on their own. These are very human networks, and that's why writing, speaking, communicating – probably for every single person listening to this podcast – is so important. Jo: Mm, yeah. Fiction Like AI 2041 and Thinking Through the Issues Jo: Have you read AI 2041 by Kai-Fu Lee and Chen Qiufan? Jamie: No. I heard a bunch of their interviews when the book came out, but I haven't read it. Jo: I think that's another good one because it's fiction – a whole load of short stories. It came out a few years ago now, but the issues they cover in the stories, about different people in different countries – I remember one about deepfakes – make you think more about the topics and help you figure out where you stand. I think that's the issue right now: it's so complex, there are so many things. I'm generally positive about AI, but of course I don't want autonomous drone weapons, you know? The Messy Reality of “Bad” Technologies Jamie: Can I ask you about that? Because this is why it's so complicated. Like you, I think nobody wants autonomous killer drones anywhere in the world. But if you right now were the defence minister of Ukraine, and your children are being kidnapped, your country is being destroyed, you're fighting for your survival, you're getting attacked every night – and you're getting attacked by the Russians, who are investing more and more in autonomous killer robots – you kind of have two choices. You can say, “I'm going to surrender,” or, “I'm going to use what technology I have available to defend myself, and hopefully fight to either victory or some kind of stand-off.” That's what our societies did with nuclear weapons. Maybe not every American recognises that Churchill gave Britain's nuclear secrets to America as a way of greasing the wheels of the Anglo-American alliance during the Second World War – but that was our programme: we couldn't afford to lose that war, and we couldn't afford to let the Nazis get nuclear weapons before we did. So there's the abstract feeling of, “I'm against all war in the abstract. I'm against autonomous killer robots in the abstract.” But if I were the defence minister of Ukraine, I would say, “What will it take for us to build the weapons we can use to defend ourselves?” That's why all this stuff gets so complicated. And frankly, it's why the relationship between fiction and nonfiction is so important. If every novel had a situation where every character said, “Oh, I know exactly the right answer,” and then they just did the right answer and it was obviously right, it wouldn't make for great fiction. We're dealing with really complex humans. We have conflicting impulses. We're not perfect. Maybe there are no perfect answers – but how do we strive toward better rather than worse? That's the question. Jo: Absolutely. I don't want to get too political on things. How AI Is Changing the Writing Life Jo: Let's come back to authors. In terms of the creative process, the writing process, the research process, and the business of being an author – what are some of the ways that you already use AI tools, and some of the ways, given your futurist brain, that you think things are going to change for us? Jamie: Great question. I'll start with a little middle piece. I found you, Jo, through GPT-5. I asked ChatGPT, “I'm coming out with this book and I want to connect with podcasters who are a little different from the ones I've done in the past. I've been a guest on Joe Rogan twice and some of the bigger podcasts. Make me a list of really interesting people I can have great conversations with.” That's how I found you. So this is one reward of that process. Let me say that in the last year I've worked on three books, and I'll explain how my relationship with AI has changed over those books. Cleaning Up Citations (and Getting Burned) Jamie: First is the highly revised paperback edition of Superconvergence. When the hardback came out, I had – I don't normally work with research assistants because I like to dig into everything myself – but the one thing I do use a research assistant for is that I can't be bothered, when I'm writing something, to do the full Chicago-style footnote if I'm already referencing an academic paper. So I'd just put the URL as the footnote and then hire a research assistant and say, “Go to this URL and change it into a Chicago-style citation. That's it.” Unfortunately, my research assistant on the hardback used early-days ChatGPT for that work. He did the whole thing, came back, everything looked perfect. I said, “Wow, amazing job.” It was only later, as I was going through them, that I realised something like 50% of them were invented footnotes. It was very painful to go back and fix, and it took ten times more time. With the paperback edition, I didn't use AI that much, but I did say things like, “Here's all the information – generate a Chicago-style citation.” That was better. I noticed there were a few things where I stopped using the thesaurus function on Microsoft Word because I'd just put the whole paragraph into the AI and say, “Give me ten other options for this one word,” and it would be like a contextual thesaurus. That was pretty good. Talking to a Robot Pianist Character Jamie: Then, for my new novel Virtuoso, I was writing a character who is a futurist robot that plays the piano very beautifully – not just humanly, but almost finding new things in the music we've written and composing music that resonates with us. I described the actions of that robot in the novel, but I didn't describe the inner workings of the robot's mind. In thinking about that character, I realised I was the first science-fiction writer in history who could interrogate a machine about what it was “thinking” in a particular context. I had the most beautiful conversations with ChatGPT, where I would give scenarios and ask, “What are you thinking? What are you feeling in this context?” It was all background for that character, but it was truly profound. Co-Authoring The AI Ten Commandments with GPT-5 Jamie: Third, I have another book coming out in May in the United States. I gave a talk this summer at the Chautauqua Institution in upstate New York about AI and spirituality. I talked about the history of our human relationship with our technology, about how all our religious and spiritual traditions have deep technological underpinnings – certainly our Abrahamic religions are deeply connected to farming, and Protestantism to the printing press. Then I had a section about the role of AI in generating moral codes that would resonate with humans. Everybody went nuts for this talk, and I thought, “I think I'm going to write a book.” I decided to write it differently, with GPT-5 as my named co-author. The first thing I did was outline the entire book based on the talk, which I'd already spent a huge amount of time thinking about and organising. Then I did a full outline of the arguments and structures. Then I trained GPT-5 on my writing style. The way I did it – which I fully describe in the introduction to the book – was that I'd handle all the framing: the full introduction, the argument, the structure. But if there was a section where, for a few paragraphs, I was summarising a huge field of data, even something I knew well, I'd give GPT-5 the intro sentence and say, “In my writing style, prepare four paragraphs on this.” For example, I might write: “AI has the potential to see us humans like we humans see ant colonies.” Then I'd say, “Give me four paragraphs on the relationship between the individual and the collective in ant colonies.” I could have written those four paragraphs myself, but it would've taken a month to read the life's work of E.O. Wilson and then write them. GPT-5 wrote them in seconds or minutes, in its thinking mode. I'd then say, “It's not quite right – change this, change that,” and we'd go back and forth three or four times. Then I'd edit the whole thing and put it into the text. So this book that I could have written on my own in a year, I wrote a first draft of with GPT-5 as my named co-author in two days. The whole project will take about six months from start to finish, and I'm having massive human editing – multiple edits from me, plus a professional editor. It's not a magic AI button. But I feel strongly about listing GPT-5 as a co-author because I've written it differently than previous books. I'm a huge believer in the old-fashioned lone author struggling and suffering – that's in my novels, and in Virtuoso I explore that. But other forms are going to emerge, just like video games are a creative, artistic form deeply connected to technology. The novel hasn't been around forever – the current format is only a few centuries old – and forms are always changing. There are real opportunities for authors, and there will be so much crap flooding the market because everybody can write something and put it up on Amazon. But I think there will be a very special place for thoughtful human authors who have an idea of what humans do at our best, and who translate that into content other humans can enjoy. Traditional vs Indie: Why This Book Will Be Self-Published Jo: I'm interested – you mentioned that it's your named co-author. Is this book going through a traditional publisher, and what do they think about that? Or are you going to publish it yourself? Jamie: It's such a smart question. What I found quickly is that when you get to be an author later in your career, you have all the infrastructure – a track record, a fantastic agent, all of that. But there were two things that were really important to me here: I wanted to get this book out really fast – six months instead of a year and a half. It was essential to me to have GPT-5 listed as my co-author, because if it were just my name, I feel like it would be dishonest. Readers who are used to reading my books – I didn't want to present something different than what it was. I spoke with my agent, who I absolutely love, and she said that for this particular project it was going to be really hard in traditional publishing. So I did a huge amount of research, because I'd never done anything in the self-publishing world before. I looked at different models. There was one hybrid model that's basically the same as traditional, but you pay for the things the publisher would normally pay for. I ended up not doing that. Instead, I decided on a self-publishing route where I disaggregated the publishing process. I found three teams: one for producing the book, one for getting the book out into the world, and a smaller one for the audiobook. I still believe in traditional publishing – there's a lot of wonderful human value-add. But some works just don't lend themselves to traditional publishing. For this book, which is called The AI Ten Commandments, that's the path I've chosen. Jo: And when's that out? I think people will be interested. Jamie: April 26th. Those of us used to traditional publishing think, “I've finished the book, sold the proposal, it'll be out any day now,” and then it can be a year and a half. It's frustrating. With this, the process can be much faster because it's possible to control more of the variables. But the key – as I was saying – is to make sure it's as good a book as everything else you've written. It's great to speed up, but you don't want to compromise on quality. The Coming Flood of Excellent AI-Generated Work Jo: Yeah, absolutely. We're almost out of time, but I want to come back to your “flood of crap” and the “AI slop” idea that's going around. Because you are working with GPT-5 – and I do as well, and I work with Claude and Gemini – and right now there are still issues. Like you said about referencing, there are still hallucinations, though fewer. But fast-forward two, five years: it's not a flood of crap. It's a flood of excellent. It's a flood of stuff that's better than us. Jamie: We're humans. It's better than us in certain ways. If you have farm machinery, it's better than us at certain aspects of farming. I'm a true humanist. I think there will be lots of things machines do better than us, but there will be tons of things we do better than them. There's a reason humans still care about chess, even though machines can beat humans at chess. Some people are saying things I fully disagree with, like this concept of AGI – artificial general intelligence – where machines do everything better than humans. I've summarised my position in seven letters: “AGI is BS.” The only way you can believe in AGI in that sense is if your concept of what a human is and what a human mind is is so narrow that you think it's just a narrow range of analytical skills. We are so much more than that. Humans represent almost four billion years of embodied evolution. There's so much about ourselves that we don't know. As incredible as these machines are and will become, there will always be wonderful things humans can do that are different from machines. What I always tell people is: whatever you're doing, don't be a second-rate machine. Be a first-rate human. If you're doing something and a machine is doing that thing much better than you, then shift to something where your unique capacities as a human give you the opportunity to do something better. So yes, I totally agree that the quality of AI-generated stuff will get better. But I think the most creative and successful humans will be the ones who say, “I recognise that this is creating new opportunities, and I'm going to insert my core humanity to do something magical and new.” People are “othering” these technologies, but the technologies themselves are magnificent human-generated artefacts. They're not alien UFOs that landed here. It's a scary moment for creatives, no doubt, because there are things all of us did in the past that machines can now do really well. But this is the moment where the most creative people ask themselves, “What does it mean for me to be a great human?” The pat answers won't apply. In my Virtuoso novel I explore that a lot. The idea that “machines don't do creativity” – they will do incredible creativity; it just won't be exactly human creativity. We will be potentially huge beneficiaries of these capabilities, but we really have to believe in and invest in the magic of our core humanity. Where to Find Jamie and His Books Jo: Brilliant. So where can people find you and your books online? Jamie: Thank you so much for asking. My website is jamiemetzl.com – and my books are available everywhere. Jo: Fantastic. Thanks so much for your time, Jamie. That was great. Jamie: Thank you, Joanna.The post Writing The Future, And Being More Human In An Age of AI With Jamie Metzl first appeared on The Creative Penn.

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Dr. Melissa Ilardo, Ph.D is a professor of evolutionary genomics and biomedical informatics at the University of Utah. Her research explores human evolution and adaptation in populations that have previously been overlooked or excluded from biological research. Her recent work looks into a population who engages in the practice of breath-hold diving & is evolving on a unique breakaway trajectory from the rest of homo sapiens on earth. SPONSORS https://hellofresh.com/danny10fm - Get 10 Free Meals + a Free breakfast for Life! https://cell.ver.so/danny - Use code DANNY to save 15% on your first order. https://butcherbox.com/danny - Get free steak in every box for a year PLUS $20 off your first box. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS https://medicine.utah.edu/faculty/melissa-ilardo https://www.superhumanlab.org https://www.nytimes.com/2018/04/19/science/bajau-evolution-ocean-diving.html https://www.instagram.com/superhumanscilab https://linkedin.com/in/melissa-ilardo FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Genomic evolution of Baju people (sea nomads) 15:00 - How long Baju can hold their breath for 21:19 - All-female Korean free divers (Haenyeo) 32:17 - Lost species of humans 42:44 - Humans won't survive the next 100,000 years 47:50 - Mother of humanity: The real "Eve" 59:48 - Humans are attracted to mates by pheromones 01:06:30 - Why assisted reproductive technology might be harmful to evolution 01:14:57 - Effects of the global population mixing & mating together 01:21:37 - Risks of CRISPR gene editing 01:30:37 - Lifespan & the grandmother hypothesis 01:37:18 - Evolution of un-contacted indigenous tribes 01:40:50 - What future humans will look like 01:49:08 - Intelligence is not genetic Learn more about your ad choices. Visit podcastchoices.com/adchoices

New weight loss drugs may portend end of “Fat Acceptance” movement; Celebs and Southerners embrace GLP-1s; Trump clears path for more access to diet drugs; Mid- and late-life exercise slash dementia risk; “Ethicists” urge more tick-borne meat allergy to save planet—as alpha-gal syndrome claims first fatality; What's wrong with the melatonin study that claims it leads to heart failure? How to detox 9-11 first-responders? Can weekend warriors obtain same benefits as regular exercisers? 

Broadcast from KSQD, Santa Cruz on 11-20-2025: Dr. Dawn discusses GLP-1 inhibitors like Zepbound and semaglutide showing unexpected benefits for addiction treatment beyond diabetes and weight loss. Patients in rehab report these drugs mute cravings for alcohol, cocaine, and cigarettes. Multiple studies show reduced substance abuse rates in users, with VA and NIH conducting trials examining brain activity and responses to triggers. With 80,000 annual drug overdose deaths and 48 million Americans having substance abuse disorders, these medications may revolutionize addiction treatment by dampening brain reward circuitry, though costs threaten healthcare budgets. A Stanford twin study found those twins assigned a vegan diet had substantially lower cholesterol, insulin, and body weight compared to their omnivore twins after several months, with LDL dropping 15mg, four pounds more weight loss, and 20% lower insulin. Dr. Dawn explains how a fungal disease decimating Central American frog populations caused 500% malaria increases in some areas. The fungus kills frogs by blocking skin electrolytes until hearts stop, eliminating tadpoles that eat mosquito larvae. Ecosystem collapses followed with algae blooms and snake population drops. She provides other examples showing how species losses affect human health, emphasizing the "one health" movement recognizing ecosystem health as fundamental to human wellbeing. An Australian study found people aged 70+ who listen to or play music regularly had 39% lower dementia rates, though causation remains uncertain. Princeton research shows music activates multiple brain regions simultaneously. Learning instruments increases gray matter, and musical memory remains intact in advanced dementia since it's stored separately from other memories. A caller discusses how modern screen-based activities provide less multisensory engagement than past social experiences like dances. Another caller describes Grover's disease causing persistent itchy skin with no known cause. Dr. Dawn recommends an elimination diet removing common allergens for one month, then reintroducing individually to identify food sensitivities triggering immune responses. Dr. Dawn explains xenotransplantation advances with genetically edited pigs beginning full-scale kidney transplant trials. Companies use CRISPR to disable genes causing immune rejection and insert human genes promoting immune tolerance. With only 10% of global kidney patients receiving organs, these could provide unlimited supply. Other innovations include kidneys with thymus tissue to teach immune tolerance and external pig liver systems as transplant bridges. She concludes noting research showing female dogs remember and prefer humans who demonstrate competence at tasks, while male dogs show no preference.

Angel Studios https://Angel.com/Herman Join the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar Today 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeIt's All One Thing: US Catholic Bishops and Treason Demanding Democrats // Are You Ready for GMO Babies?  // To The Progressive Church, Satan is a Christian.Episode links:Democrats Demand Our Military Members Revolt Against The President.Special Pastoral Message on Immigration by the Bishops of the United StatesCam Higby just CALLED OUT the mayor of Muslim-dominated Dearborn Michigan at the council meetingOpenAI CEO Sam Altman and His Husband Are Funding the Creation of Genetically Engineered Babies; The rebirth of Frankenstein in the era of CRISPR and AI Elon Musk on how Optimus will provide access to the best medical care for anyone in the world:Poll: 4 In 5 Americans Are ‘Concerned' About Silicon Valley's Unregulated Embryo-Screening SchemeGene-Editing Human Embryos: A Doomed Technological Catastrophe; Epidemiologist Nicolas Hulscher on Real America's Voice  Blaire White professes to be Christian:

Angel Studios https://Angel.com/Herman Join the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar THIS Thursday 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeMarjorie Taylor Greene: Lying or Repenting? // The Epstein Connection to Sam Altman's Gene-Editing of Babies // On Ben Shapiro's Million Dollars to a Christian Group… Episode Links:Raskin: We are a big tent. We must be a huge, vast tent. I say this is a party that's got room for Marjorie Taylor Greene if she wants to come over.JFK's grandson Jack Schlossberg: "President Trump is so obsessed with the Kennedys and the Kennedy name that he caged one and put in his cabinet— a rabid dog in his cabinet. Put a collar on my cousin RFK Jr and has him there barking, spreading lies and misinformation."An illegal alien attacked a woman with a hammer while she was out jogging in Plano, Texas, Thursday. The victim fought back even after being struck twice, causing the 17-year-old attacker, Sergio Noe De Nova Duarte, to flee the scene. Fox & Friends: “The 17-year-old suspect was quickly arrested. Police say when his fingerprints were processed, they received a notification to place him under an ICE hold.” “So far, he's been charged with aggravated kidnapping with bodily injury and is now being held by ICE.”MTG just took full ownership on CNN and it's one of the most unexpected moments of the year. When asked why she only denounced Trump's rhetoric after it was directed at her, she didn't deflect. She owned it: “That's fair criticism… and I would like to say humbly, I'm sorry for taking part in the toxic politics. It's very bad for our country.”Elon Musk on how Optimus will provide access to the best medical care for anyone in the world:OpenAI CEO Sam Altman and His Husband Are Funding the Creation of Genetically Engineered Babies; The rebirth of Frankenstein in the era of CRISPR and AILarry Summers steps back from public roles after House release of Epstein correspondenceFormer Harvard president says he's 'deeply ashamed' of continued communication with disgraced financierBen Shapiro donated $1M to TPUSA to help "bring people back to Christ, and bring people back to church, and back to biblical values," as Charlie wanted. The nonstop slander against him is clearly well-funded and highly organized.According to Ben Shapiro himself, Jesus was a "bad guy" who tried to overthrow the Roman Empire and was killed for "his troubles." - "I don't believe in the Jesus."Do non-Jews or non-Noahides go to heaven?What Are the Seven Noahide Laws?

In this special episode of Robin's Nest, we're joined by Dr. George Church, a world-renowned geneticist and one of the leading minds behind the Human Genome Project, for a conversation about the amazing ways science is helping us understand, protect and even restore life on Earth.Dr. Church takes us inside the frontier of synthetic biology, from the origins of CRISPR and gene editing to the bold promise of de-extinction, conservation technology and genetic equity. The discussion spans his groundbreaking work with Colossal Biosciences, where efforts to revive the woolly mammoth and other lost species aim to restore ecosystems and rethink what “saving nature” means in the 21st century.Listeners will hear Dr. Church reflect on the ethics and responsibilities of rewriting life's code, the potential for genetic engineering to combat biodiversity loss, and why he believes “extinction doesn't have to be forever.” This episode explores how technology and conservation can work hand-in-hand to heal the planet.A fascinating journey into the science shaping our shared future, and a reminder that innovation, guided by compassion and curiosity, may yet help us write a better story for life on Earth.

Broadcast from KSQD, Santa Cruz on 11-13-2025: Dr. Dawn discusses a New England Journal of Medicine study examining radiation exposure from medical imaging in over 4 million children showing increased hematological cancer risk. Head and brain CTs deliver highest bone marrow doses, with under-1-year-olds receiving 20 milligrays compared to background radiation of 1 milligray yearly. The study found 3,000 cancers in 4 million children over roughly 10 years, with relative risk increasing 1.6-fold per CT scan. However, methodological flaws include combining US and Canadian cohorts with different data quality, potential reverse causation where imaging detected pre-existing cancers, and arbitrary 6-month latency assumptions are significant flaws in this study.. Despite small absolute risk increases given low baseline cancer rates, she encourages parents to question necessity of repeat scans and request alternatives like MRI when appropriate. She reports on cutting-edge CRISPR therapy using lipid nanoparticles to deliver molecular scissors targeting the ANGPTL3 gene controlling LDL cholesterol production. Recent setbacks in several other CRISPR trials raise issues for unexplained liver toxicity. Concerns include off-target gene editing effects and partially repaired DNA creating mutated proteins triggering autoimmune reactions. Dr. Dawn emphasizes restricting gene therapy to life-threatening genetic diseases with no alternatives until safety improves. Stanford scientists used AI model Evo trained on 9 trillion gene samples to design 300 new bacteriophages from scratch, with 16 phages successfully killing E. coli bacteria. AI tools now predict protein structures, design custom drugs, create antivenoms, invent antibiotics, and break down PFAS forever chemicals. The research represents evolution through computation and requires guardrails on AI's ability to manipulate biological structures. An emailer shares the Rosencare model where hotel chain owner Harris Rosen created self-insured health coverage featuring direct provider contracting, imaging facilities charging one-third to one-half traditional costs, transparent pharmacy benefit management, and zero or $5 primary care copays. Employees receive proactive screening for colonoscopies, mammograms, cholesterol, diabetes, and hypertension during clinic visits. Ninety percent of medicines including insulin cost nothing, with remaining drugs $0-25, and hospital admissions cost flat $750. The model saved $600 million while providing superior preventive care by eliminating insurance middlemen and focusing on early chronic disease detection when 75-85% of costs originate. Dr. Dawn explains abdominophrenic dyssynergia causing bloating unrelated to gas or food. The diaphragm descends and abdominal wall muscles relax, pushing organs forward after meals. CT scans showed lettuce-related bloating involved no intestinal gas changes but demonstrated this abnormal muscle reflex. Randomized trials showed biofeedback training with chest-lifting and abdominal wall contracting exercises before and after eating for four weeks improved symptoms 66%. She warns that constant bloating in postmenopausal women unrelated to eating requires ovarian cancer screening. She discusses how genes drive personality using dopamine receptor gene DRD4 polymorphisms as an example. The 7-repeat variant present in 48% of Americans creates receptors binding dopamine poorly, associating with ADHD, pathological gambling, alcoholism, drug dependence, and bulimia, plus personality traits of novelty-seeking, impulsiveness, and optimism. The 2-repeat DRD4 variant common in Asia correlates with lower anger and higher forgiveness. DRD2 variations enhance the memory of negative outcomes, creating pessimistic bias and avoidance behavior. She presents the KETO trial showing "lean mass hyper-responder phenotype" where very low-carbohydrate dieters averaging age 55 maintained LDL cholesterol of 272 for five years but showed identical coronary artery calcium scores and plaque burden as matched controls with LDL under 150. Despite extreme LDL elevation, the very low insulin levels from carbohydrate restriction prevent LDL oxidation, the inflammatory "loading" process enabling arterial damage. She concludes with unusual cancer symptom where recurrent pain in specific body locations after alcohol consumption, lasting 1-2 days, occurs in 5% of Hodgkin lymphoma patients and in other cancers when alcohol induced blood vessel dilation and inflammatory chemical release in cancer-containing lymph nodes causes pain after drinking.

TUCKER PLAYS THE HAARP - 11.12.2025 - #891 BestPodcastintheMetaverse.com Canary Cry News Talk #891 - 11.12.2025 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com   Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers LX Protocol BARON of the Berrean Protocol*** Sir Jamey Not the Lanister***   Producers of TREASURE (CanaryCry.Support) Mark T, Mrs TinFoilHatMan, Veronica D, Sir Scott Knight of Truth, Sir Casey the Shield Knight   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM     MONEY 5:40 Last penny ever minted today in Philadelphia    BIBLICAL 48:55 The U.S. saw vivid northern lights as far south as Florida — and more could be coming (NPR) → Northern Lights over America (X)    GEOENGINEERING 51:54 Dane Wigington on Tucker Carlson (huffpo) Dane wigington on newsmax Dane Wigington on Canary Cry Radio   DNA 1:30:50 Startup Secretly Working to Gene-Hack Human Baby (Futurism) → US baby receives first-ever customized CRISPR treatment (March 2025, Live Science)   ECONOMIST COVER 2:02:42 The Economist Group - The Economist launches The World Ahead 2026–with rich countries living beyond their means, the risk of a bond-market crisis is growing   TRUMP/EPSTEIN  New Epstein Emails Alleged Trump Knew of His Conduct (NY Times) released Epstien emails Fishy (X)   AI/BEAST SYSTEM 2:08:24 Woman marries AI character she made on ChatGPT after real marriage gets called off (Dextero)   FLIPPY UPDATE Global Robot Arms Market to Reach USD 36.2 Billion by 2035, Driven by Precision Automation and Smart Manufacturing Integration, Reports Fact.MR (Open PR)   EXECUTIVE PRODUCERS TALENT/TIME END

Howie and Harlan are joined by Harvard internist Jerry Avorn to discuss his research on the pharmaceutical industry and his work promoting evidence-based prescribing. Harlan highlights new results from the American Heart Association meeting, including a one-time CRISPR-based therapy for high cholesterol; Howie reports on an outbreak of infant botulism. Show notes: Research from the American Heart Association Meeting "Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3" "First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides" "Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial" "PCSK9 medication plus statin may help lower cholesterol after heart transplant" "Investigational daily pill lowered bad cholesterol as much as injectables" Jerry Avorn Science Direct: Academic Detailing Jerry Avorn: "Principles of Educational Outreach ('Academic Detailing') to Improve Clinical Decision Making" Alosa Health FDA: Accelerated Approval Jerry Avorn: Rethinking Medications: Truth, Power, and the Drugs You Take FDA: Direct-to-Consumer (DTC) Advertisements H.R.5952 - Prescription Drug User Fee Act of 1992 FDA: FY 2025 FDA Budget Summary Centers for Medicare & Medicaid Services: Open Payments  H.R.3590 - Patient Protection and Affordable Care Act "Aducanumab Discontinued as an Alzheimer's Treatment" FDA: ELEVIDYS Brigham and Women's Hospital & Harvard Medical School: Division of Pharmacoepidemiology and Pharmacoeconomics Amazon.com: Featured comments on Rethinking Medications Infant Botulism California Department of Public Health: "Outbreak of Infant Botulism Linked to ByHeart Infant Formula" California Department of Public Health: Infant Botulism Treatment and Prevention Program CDC: "Infant Botulism Outbreak Linked to Infant Formula, November 2025" "ByHeart recalls all baby formula sold nationwide as infant botulism outbreak grows" California Department of Public Health: What is BabyBIG? California Department of Public Health: Postponement of BabyBIG Fee Increase California Department Of Public Health: Invoice and Purchase Agreement for BabyBIG In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

TWiP discusses a 41-year long human infection with Schistosoma mansoni, and CRISPR screens that reveal genes essential for Cryptosporidium survival in the host intestine. Hosts: Vincent Racaniello, Daniel Griffin, and Christina Naula Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode Join the MicrobeTV Discord server 41 year old Schistosoma infection (J Travel Med) Genes essential for Cryptosporidium survival in host intestine (Nat Comm) Become a patron of TWiP  Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees

To Find Deplorable Janet--> https://open.spotify.com/show/3K5Xi9LugxNdI06GXSIjAp?si=m5hPD7OsS6eim1jACk84ewTo sign up for our Patreon go to-> Patreon.com/cultofconspiracypodcast To Join the Cajun Knight Patreon---> Patreon.com/cajunknight To Find The Cajun Knight Youtube Channel---> click hereTo Invest In Gold & Silver, CHECK OUT—-> Www.Cocsilver.com 10% OFF Rife Machine---> https://rifemachine.myshopify.com/?rfsn=7689156.6a9b5c To find the Meta Mysteries Podcast---> https://open.spotify.com/show/6IshwF6qc2iuqz3WTPz9Wv?si=3a32c8f730b34e79 50% OFF Adam&Eve products---> :adameve.com (promo code : CULT) To Sign up for our Rokfin go to --> Rokfin.com/cultofconspiracy Become a supporter of this podcast: https://www.spreaker.com/podcast/cult-of-conspiracy--5700337/support.

We've entered a new age. Where nature once took a million years to make a few genetic changes, scientists can now make billions in an afternoon — and even imagine adapting humans for life beyond Earth.George Church, a Harvard geneticist, pioneer of the Human Genome Project, and founder of more than 50 biotech companies, helped lay the foundation for CRISPR, personal genomics, and even de-extinction.In this episode, he explains how biotechnology, AI, and materials science are converging to transform life itself -  from reversing aging and curing disease to resurrecting lost species like the woolly mammoth, and one day, helping humanity thrive among the stars.

Humans and nature have always coexisted. But, human intervention makes our modern world look very different than it once did. This episode, host Dr. Samantha Yammine digs into how humans are reshaping the wild. Sam speaks to Dr. Harland Patch about the decline of insect populations around the world and how we can provide better environments for pollinators. She also dives into the world of CRISPR gene editing among Argentinian polo horses and why so many people seem to be getting diagnosed with Lyme disease. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.